154 related articles for article (PubMed ID: 11249825)
1. Penicillin-resistant streptococcus pneumoniae: review of moxifloxacin activity.
Dalhoff A; Krasemann C; Wegener S; Tillotson G
Clin Infect Dis; 2001 Mar; 32 Suppl 1():S22-9. PubMed ID: 11249825
[TBL] [Abstract][Full Text] [Related]
2. Bactericidal activity of moxifloxacin against pneumococci.
Levy D; Berche P
Clin Microbiol Infect; 2001 Jan; 7(1):47-8. PubMed ID: 11284948
[No Abstract] [Full Text] [Related]
3. Pharmacokinetic and pharmacodynamic predictors of antimicrobial efficacy: moxifloxacin and Streptococcus pneumoniae.
Schentag JJ
J Chemother; 2002 Feb; 14 Suppl 2():13-21. PubMed ID: 12003136
[TBL] [Abstract][Full Text] [Related]
4. Clinical perspectives on new antimicrobials: focus on fluoroquinolones.
Talan DA
Clin Infect Dis; 2001 Mar; 32 Suppl 1():S64-71. PubMed ID: 11249831
[TBL] [Abstract][Full Text] [Related]
5. Streptococcus pneumoniae: does antimicrobial resistance matter?
Lynch JP; Zhanel GG
Semin Respir Crit Care Med; 2009 Apr; 30(2):210-38. PubMed ID: 19296420
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of moxifloxacin for treatment of penicillin-, macrolide- and multidrug-resistant Streptococcus pneumoniae in community-acquired pneumonia.
Fogarty C; Torres A; Choudhri S; Haverstock D; Herrington J; Ambler J
Int J Clin Pract; 2005 Nov; 59(11):1253-9. PubMed ID: 16236076
[TBL] [Abstract][Full Text] [Related]
7. Bactericidal activity of moxifloxacin compared to grepafloxacin and clarithromycin against Streptococcus pneumoniae and Streptococcus pyogenes investigated using an in vitro pharmacodynamic model.
Esposito S; Noviello S; Ianniello F
J Chemother; 2000 Dec; 12(6):475-81. PubMed ID: 11154028
[TBL] [Abstract][Full Text] [Related]
8. Moxifloxacin (Avelox): an 8-methoxyquinolone antibacterial with enhanced potency.
Ball P
Int J Clin Pract; 2000 Jun; 54(5):329-32. PubMed ID: 10954961
[TBL] [Abstract][Full Text] [Related]
9. Concentration-dependent killing of antibiotic-resistant pneumococci by the methoxyquinolone moxifloxacin.
Klugman KP; Capper T
J Antimicrob Chemother; 1997 Dec; 40(6):797-802. PubMed ID: 9462430
[TBL] [Abstract][Full Text] [Related]
10. Penicillin enhances the toll-like receptor 2-mediated proinflammatory activity of Streptococcus pneumoniae.
Moore LJ; Pridmore AC; Dower SK; Read RC
J Infect Dis; 2003 Oct; 188(7):1040-8. PubMed ID: 14513425
[TBL] [Abstract][Full Text] [Related]
11. Comparative susceptibility to penicillin and quinolones of 1385 Streptococcus pneumoniae isolates. Austrian Bacterial Surveillance Network.
Buxbaum A; Straschil U; Moser C; Graninger W; Georgopoulos A
J Antimicrob Chemother; 1999 May; 43 Suppl B():13-8. PubMed ID: 10382870
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of moxifloxacin against common clinical bacterial isolates in Taiwan.
Sheng WH; Wang JT; Chen YC; Chang SC; Luh KT
J Microbiol Immunol Infect; 2001 Sep; 34(3):178-84. PubMed ID: 11605808
[TBL] [Abstract][Full Text] [Related]
13. Comparative in vitro activity of moxifloxacin by E-test against Streptococcus pyogenes.
Amábile-Cuevas CF; Hermida-Escobedo C; Vivar R
Clin Infect Dis; 2001 Mar; 32 Suppl 1():S30-2. PubMed ID: 11249826
[TBL] [Abstract][Full Text] [Related]
14. E test for studying in vitro activity of seven antimicrobial agents against penicillin-susceptible and penicillin-resistant pneumococci.
Li J; Zhang Y; Chen Y; Hao F; Chen Y
Chin Med J (Engl); 2000 Jul; 113(7):628-31. PubMed ID: 11776034
[TBL] [Abstract][Full Text] [Related]
15. In vitro interactions of LytA, the major pneumococcal autolysin, with two bacteriophage lytic enzymes (Cpl-1 and Pal), cefotaxime and moxifloxacin against antibiotic-susceptible and -resistant Streptococcus pneumoniae strains.
Rodríguez-Cerrato V; García P; Del Prado G; García E; Gracia M; Huelves L; Ponte C; López R; Soriano F
J Antimicrob Chemother; 2007 Nov; 60(5):1159-62. PubMed ID: 17827138
[TBL] [Abstract][Full Text] [Related]
16. Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniae.
Saravolatz L; Manzor O; Check C; Pawlak J; Belian B
J Antimicrob Chemother; 2001 Jun; 47(6):875-7. PubMed ID: 11389122
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
Odenholt I; Cars O
J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
[TBL] [Abstract][Full Text] [Related]
18. Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study).
Jacobs E; Dalhoff A; Korfmann G
Int J Antimicrob Agents; 2009 Jan; 33(1):52-7. PubMed ID: 18835763
[TBL] [Abstract][Full Text] [Related]
19. In vitro antibacterial activity of beta-lactams and non-beta-lactams against Streptococcus pneumoniae isolates from Sydney, Australia.
Gosbell IB; Fernandes LA; Fernandes CJ
Pathology; 2006 Aug; 38(4):343-8. PubMed ID: 16916725
[TBL] [Abstract][Full Text] [Related]
20. Moxifloxacin: a comparison with other antimicrobial agents of in-vitro activity against Streptococcus pneumoniae.
Reinert RR; Schlaeger JJ; Lütticken R
J Antimicrob Chemother; 1998 Dec; 42(6):803-6. PubMed ID: 10052905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]